Curriculum Vitae: William M Townsend

Name: Dr William M Townsend
Job title: Consultant Haematologist and Honorary Associate Professor of Haematology
Clinical lead for Lymphoma

Qualifications and awards

Undergraduate degrees: MBChB with Hons *(Distinction in Medicine)* - Birmingham, 2004
BMedSc *(Pub Health and Epidemiology)* II(I) Birmingham, 2002

Distinctions/Honours: Overall MBChB honours degree with Distinction in Medicine.

Postgraduate Qualifications: MD (research) Kings College London (2018)
FRCPath (Haematology) *(November 2015)*
MRCP (UK) *(July 2007)*

Current employment and key roles:

- Consultant Haematologist, Clinical Lead for lymphoma service, UCLH NHS Trust (2017-present)
- Honorary Associate Professor of Haematology at UCL (2022-present)
- UCL Clinical lead for haematology trials at CRUK Cancer Trials centre (2022-present)
- Lead for lymphoma clinical department at UCLH (2024-present)
- Lead for early phase clinical trials at UCLH (2017-present)
- Speciality lead for haematology trials at North Thames Research Network (2019-present)
- Member of UK lymphoma research group low-and-high-grade NHL trials groups (2018-present)

Previous employment history

Feb 2015 – Dec 2016	Haematology Training programme UCLH NHS Trust
Feb 2011-Feb 2015	Lymphoma Clinical Fellow – CRUK/UCL Cancer Trials Centre
March 2009-Feb 2011	Haematology Training rotation – UCLH NHS Foundation Trust
August 2008-March 2009	Haematology ST3 - Norfolk and Norwich University Hospital
August 2005-August 2008	SHO rotation Nottingham University Hospitals and UCLH
August 2004-August 2005	PRHO University Hospital Birmingham

Selected Publications

Chaganti S, Dulobdas V, Wilson MR, Tucker D, **Townsend W**, Parry-Jones N, Lewis D, Fox CP, Osborne W. Clinical management of bispecific antibody therapy for lymphoma: A British Society for Haematology Good Practice Paper. Br J Haematol. 2025 Oct;207(4):1227-1241. doi: 10.1111/bjh.70018. Epub 2025 Sep 5. PMID: 40910188.

Northend M, Wilson W, Ediriwickrema K, Clifton-Hadley L, Qian W, Rana Z, Martin TL, **Townsend W**, Young M, Miall F, Cunningham D, Walewski J, Ferhanoglu B, Linton K, Johnston A, Seymour JF, Linch DC, Ardeshna KM. Early rituximab monotherapy versus watchful waiting for

advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial. Lancet Haematol. 2025 May;12(5):e335-e345. doi: 10.1016/S2352-3026(25)00034-1. PMID: 40306831.

Abramson JS, Ku M, Hertzberg M, Huang HQ, Fox CP, Zhang H, Yoon DH, Kim WS, Abdulhaq H, **Townsend W**, Herbaux C, Zaucha JM, Zhang QY, Chang H, Liu Y, Cheah CY, Ghesquieres H, Simko S, Orellana-Noia V, Ta R, Relf J, Dixon M, Kallemeijn M, Mulvihill E, Huang H, Lundberg L, Gregory GP. Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. Lancet. 2024 Nov 16;404(10466):1940-1954. doi: 10.1016/S0140-6736(24)01774-4. PMID: 39550172.

Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study. **Townsend W,** Hiddemann W, Buske C, Cartron G, Cunningham D, Dyer MJS, Gribben JG, Phillips EH, Dreyling M, Seymour JF, Grigg A, Trotman J, Lin TY, Hong XN, Kingbiel D, Nielsen TG, Knapp A, Herold M, Marcus R. Hemasphere. 2023 Jun 30;7(7):e919. doi: 10.1097/HS9.0000000000000919. eCollection 2023 Jul.
PMID: 37404773

CAR T in patients with large B-cell lymphoma not fit for autologous transplant.
Kuhnl A, Kirkwood AA, Roddie C, Menne T, Tholouli E, Bloor A, Besley C, Chaganti S, Osborne W, Norman J, Gibb A, Sharplin K, Cuadrado M, Correia de Farias M, Cheok K, Neill L, Latif AL, González Arias C, Uttenthal B, Jones C, Johnson R, McMillan A, Sanderson R, **Townsend W**. Br J Haematol. 2023 Jul;202(1):65-73. doi: 10.1111/bjh.18810. Epub 2023 Apr 20.

Impact of positron emission tomography - computed tomography status on progression-free survival for relapsed follicular lymphoma patients undergoing autologous stem cell transplantation. Eyre TA, Barrington SF, Okosun J, Abamba C, Pearce RM, Lee J, Carpenter B, Crawley CR, Bloor AJC, Gilleece M, Nicholson E, Shah N, Orchard K, Malladi R, **Townsend WM.** Haematologica. 2023 Mar 1;108(3):785-796. doi: 10.3324/haematol.2021.280287.

Results of a UK real world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory large B-cell lymphoma. Northend M, Wilson W, Osborne W. **Townsend WM.** Blood Adv. 2022 Jan 12:bloodadvances.2021005953. doi: 10.1182/bloodadvances.2021005953. Online ahead of print.PMID: 35020818

British Society for Haematology. Guideline for the first-line management of Classical Hodgkin Lymphoma - A British Society for Haematology guideline.Follows GA, Barrington SF, Bhuller KS, Culligan DJ, Cutter DJ, Gallop-Evans E, Kassam S, Osborne W, Sadullah S, **Townsend W**, Uttenthal BJ, Collins GP; Br J Haematol. 2022 Feb 22. doi: 10.1111/bjh.18083. Epub ahead of print. PMID: 35191541.

Kuhnl A, Roddie C, Kirkwood AA, Menne T, Cuadrado M, Marzolini MAV, Osborne W, Sanderson R, O'Reilly M, **Townsend W**, Benjamin R, Potter V, Patten PEM, Yallop D, Voo S, Petrides GS, Mulholland N, Kayani I. Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma. Blood Adv. 2022 Jan 11;6(1):321-326. doi: 10.1182/bloodadvances.2021005807. PMID: 34700342; PMCID: PMC8753214.

A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma. Collins GP, Eyre TA, Schmitz-Rohmer D, **Townsend W,** Popat R, Giulino-Roth L, Fields PA, Krasniqi F, Soussain C, Stathis A, Andjelkovic N, Cunningham D, Mandic D, Radulovic S, Tijanic I, Horowitz NA, Kurtovic S, Schorb E, Schmidt C, Dimitrijević S, Dreyling M Hemasphere. 2021 Oct 27;5(11):e656. doi: 10.1097/HS9.0000000000000656. PMID: 34901759; PMCID: PMC8660000.

Efficacy and Safety Exposure-Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma. Hess B, **Townsend W**, Ai W, Stathis A, Solh M, Alderuccio JP, Ungar D, Liao S, Liao L, Khouri L, Zhang X, Boni J. AAPS J. 2021 Dec 10;24(1):11. doi: 10.1208/s12248-021-00660-3. PMID: 34893942.

Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial. Herrera AF, Burton C, Radford J, Miall F, **Townsend W**, Santoro A, Zinzani PL, Lewis D, Fowst C, Brar S, Huang B, Thall A, Collins GP. Blood Adv. 2021 Sep 14;5(17):3387-3396. doi: 10.1182/bloodadvances.2021004511. PMID: 34477818; PMCID: PMC8525219.

Novel Therapy Approaches to Follicular Lymphoma. Northend M, **Townsend W**. Drugs. 2021 Mar;81(4):453-469. doi: 10.1007/s40265-020-01446-1. PMID: 33616890.

The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series. McMillan A, O'Neill AT, **Townsend W,** Lambert J, Virchis A, Shah R, Menezes L, Humphries P, Von Both K, Grandage V, Carpenter B, Hough R, Ardeshna KM, Daw S. Br J Haematol. 2021 Feb;192(3):e84-e87. doi: 10.1111/bjh.17274. Epub 2021 Jan 10. PMID: 33426648.

Phase I, first-in-human trial of Bruton's tyrosine kinase inhibitor M7583 in patients with B-cell malignancies. Jurczak W, Rule S, **Townsend W**, Tucker D, Sarholz B, Scheele J, Dyroff M, Gribben JG, Długosz-Danecka M, Zinzani PLLeuk Lymphoma. 2021 Oct;62(10):2392-2399. doi: 10.1080/10428194.2021.1913139. Epub 2021 Apr 24. PMID: 33896333.

Treatment of classical Hodgkin lymphoma in young adults aged 18-30 years with a modified paediatric Hodgkin lymphoma protocol. Results of a multicentre phase II clinical trial (CRUK/08/012). **Townsend W**, Leong S, Hoskin P, Diez P, Patrick P, Linch D, Wong WL, Kayani I, Sanghera B, …Clifton-Hadley L, Ardeshna K. Br J Haematol. 2020 Apr;189(1):128-132.

The investigation and management of follicular lymphoma. McNamara C, Montoto S, Eyre TA, Ardeshna K, Burton C, Illidge T, Linton K, Rule S, **Townsend W**, Wong WL, McKay P. Br J Haematol. 2020 Jun 24. doi: 10.1111/bjh.16872.

The architecture of neoplastic follicles in follicular lymphoma; analysis of the relationship between the tumor and follicular helper T-cells. **Townsend W,** Pasikowska M, Yallop D, Phillips E, Patten P, Salisbury J, Marcus R, Pepper A, Devereux S. Haematologica. 2020 Jun;105(6):1593-1603.

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. Robert Marcus, Andrew Davies, John F. Seymour, **William Townsend**, et al. N Engl J Med 2017; 377:1331-1344

A Phase II Clinical Trial of Fludarabine and Cyclophosphamide Followed by Thalidomide for Angioimmunoblastic T-cell Lymphoma. An NCRI Clinical Trial. CRUK number C17050/A5320. **W Townsend**, R Johnson, N Counsell, P Smith, C Rudin. Leukaemia and Lymphoma. 57; 2016.

Improved intensive care unit survival for critically ill allogeneic haematopoietic stem cell transplant recipients following reduced intensity conditioning. **W Townsend,** A Holroyd, A. Goldstone, D Linch, K Thomson, E Morris. *British Journal of Haematology.* 2013, **161**(4) 578-86.

Seminar in Hodgkin Lymphoma in Adults. **W Townsend** and D Linch. *Lancet* 2012. 380(9844): 836-847

Invited talks and presentations:

I have a national and international reputation for delivering talks and presentations on novel therapeutic strategies in lymphoma helping to educate and shape clinical practice in a diverse range of countries:

Jan 2026:	Invited speaker at Middle East Haematology Conference, Dubai, UAE, 2026
Sept 2025:	Invited speaker at Echo Haematology Meeting, Tokyo, Japan, 2025
Sept 2025:	Lecture tour of Malaysia
June 2025:	'Meet the expert' @ ICML, Lugano, Switzerland, 2025
Jan 2025:	Invited speaker at Taiwan annual haematology summit, Taipei, 2025
Jan 2025:	Lecture tour of Singapore and Taiwan
June 2024:	'Meet the expert' @ EHA, Madrid, Spain, 2024

Clinical Trials Experience:

- I am a leader in the field of clinical trials in lymphoma with a focus on novel therapeutic strategies
- I am/have been Principal investigator on 12 phase 1-2 clinical trials and 4 phase 3 trials in the field of malignant haematology (lymphoma)
- I have been / am currently National Chief Investigator on 5 clinical trials
- Chief Investigator for PORTAL Academic Trial (Sponsor: UCL CTC, Funder, Roche)
- I have been a member of several trial steering committees, dose escalation committees and Trial Management Groups
- I am an active member of the UK Lymphoma Research Group High- and Low-grade lymphoma sub-groups
- I have been a member of a data monitoring safety committee for a phase 3 trial
- I have published 32 papers and guidelines on lymphoma (including 6 as first author, 5 as senior (last) author)

Grants and awards:

Lymphoma Research Trust: project grant and Research Fellow Grant	2025: £583,000 for the UCL CTC project grant
Full trial grant from Roche	2024: £1.25 million for the PORTAL trial (Investigator initiated trial with UCL CTC)
British Society Haematology (in conjunction with Roger Counter Foundation:	2012: £15,000 For investigation into the Follicular Lymphoma microenvironment (as part of MD Research Degree)
Leukaemia & Lymphoma research (Bloodwise) Grant 10008	2013: Awarded grant of £30,000 as a supplement to grant 10008 for investigation into the Follicular Lymphoma microenvironment (as part of MD Research Degree)

Electronic Signature: **Date: 13.01.2026**